Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
A MoU was signed between Ministry of Ayush and Ministry of Tribal Affairs to collaborate in Ayush sector
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
The newest facility has all the core specialties like Obstetrics and Gynaecology, Orthopaedics, Neurology, Cardiology, Paediatrics, General Surgery, and Urology
Revenue from operations up 26% to Rs. 768 crores
He is a seasoned business leader with a successful track record of over 26 years across local and area roles within the pharmaceutical industry
For the last ten financial years, the company has posted healthy performance with its revenue from operations growing at 15% CAGR and net profit at 23% CAGR
Subscribe To Our Newsletter & Stay Updated
